. . . . "Metohexital"@en . "The onset of toxicity following an overdose of intravenously administered methohexital will be within seconds of the infusion. If methohexital is administered rectally or is ingested, the onset of toxicity may be delayed. The manifestations of an ultrashort-acting barbiturate in overdose include central nervous system depression, respiratory depression, hypotension, loss of peripheral vascular resistance, and muscular hyperactivity ranging from twitching to convulsive-like movements. Other findings may include convulsions and allergic reactions. Following massive exposure to any barbiturate, pulmonary edema, circulatory collapse with loss of peripheral vascular tone, and cardiac arrest may occur."@en . . . . . . . . . . "Methohexital"@en . . "Methohexital"@en . . . . . . . . . "The absolute bioavailability following rectal administration of methohexital is 17%."@en . "Excretion occurs via the kidneys through glomerular filtration."@en . "Methohexital binds at a distinct binding site associated with a Cl^- ionopore at the GABA_A receptor, increasing the duration of time for which the Cl^- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged."@en . "Methohexitalum"@en . . " "@en . . . "5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione"@en . . "5.6 ± 2.7 minutes"@en . "(+-)-5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid"@en . . . . . . . . . . . "5-Allyl-5-(3-hexyn-2-yl)-1-methylbarbituric acid"@en . "73%"@en . "Humans and other mammals"@en . "Methohexital is indicated for use as an intravenous anaesthetic. It has also been commonly used to induce deep sedation."@en . " "@en . . . "5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione"@en . . . . . "approved"@en . "Methohexitone"@en . . "151-83-7"@en . "An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia. [PubChem]"@en . . "alpha-DL-1-Methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituric acid"@en . . . . . .